Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens

Leukemia & Lymphoma
Yair HerishanuElla Naparstek

Abstract

Treatment with intensive chemotherapy regimens is frequently complicated by severe thrombocytopenia. During the period of severe thrombocytopenia, anticoagulant treatment is not uncommonly indicated for thromboembolic events or thromboprophylaxis in these patients. We report 10 hematological patients treated with intensive chemotherapy protocols that were anticoagulated with enoxaparin for catheter related central venous thrombosis and thromboprophylaxis. During the period of severe thrombocytopenia the dosages of enoxaparin were reduced and no major bleeding occurred. Based on our experience we suggest that reduced dosages of low molecular weight heparins may be used relatively safely during transient severe thrombocytopenia.

References

Oct 1, 1994·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·J HolstP B Ostergaard
Sep 4, 1997·The New England Journal of Medicine·J I Weitz
Jun 5, 1999·Seminars in Thrombosis and Hemostasis·R D Bona
Dec 21, 2000·Journal of Thrombosis and Thrombolysis·D A FrankA D van den Abbeele
Feb 7, 2001·Chest·M N LevineC Kearon
Sep 11, 2001·Acta Haematologica·M Monreal, E Davant

❮ Previous
Next ❯

Citations

Feb 27, 2013·Journal of Thrombosis and Thrombolysis·Gerald A Soff
Sep 28, 2012·Current Opinion in Oncology·Anna FalangaLaura Russo
Nov 21, 2007·Hematology·Anna Falanga, Frederick R Rickles
Sep 12, 2009·Thrombosis Research·Davide ImbertiUNKNOWN Italian Society for Thrombosis and Haemostasis
Jul 3, 2013·Journal of Thrombosis and Haemostasis : JTH·M CarrierUNKNOWN Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH
Aug 8, 2014·Journal of Thrombosis and Haemostasis : JTH·M Di NisioUNKNOWN Subcommittee on Haemostasis and Malignancy
Aug 7, 2013·American Journal of Hematology·Nataliya MarJames J Vredenburgh
Aug 15, 2015·Future Oncology·Gaurav Goyal, Vijaya Raj Bhatt
Jul 16, 2014·Clinical Lymphoma, Myeloma & Leukemia·Riccardo ColomboRoberto Castelli
Jul 12, 2013·Blood·Agnes Y Y Lee, Erica A Peterson
Oct 21, 2016·American Journal of Hematology·Nabin KhanalVijaya R Bhatt
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Agnes Y Y Lee
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna Falanga, Marina Marchetti
Jul 16, 2014·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Katrina M BabiloniaToby C Trujillo
Feb 23, 2018·Internal Medicine Journal·Linda S YangDamian Dowling
Jan 13, 2018·VASA. Zeitschrift für Gefässkrankheiten·Minna Voigtlaender, Florian Langer
Mar 3, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Alexandra Brown
Mar 6, 2016·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Rami B IbrahimPhilip Kuriakose
Feb 17, 2017·Journal of Thrombosis and Thrombolysis·Simon ManthaGerald A Soff
Oct 24, 2018·Research and Practice in Thrombosis and Haemostasis·Bethany R Samuelson BannowMarc Carrier
Dec 11, 2019·Experimental and Therapeutic Medicine·Roua Anamaria IorgaCamelia Cristina Diaconu
Sep 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jenna LamSamantha O Luk
Oct 2, 2021·Cancer Medicine·Mariana Bastos-OreiroCristina Pascual Izquierdo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.